CYduct Diagnostics Inc (CYDX)

[slazenger7]

After the coming Canadian expansion is documented and increased sales in U.S. are reported, price increase will follow. Strategic partnership that could be the outcome of ongoing SNDY negotiations would be a game changer here. .004 short term target price depending on partnership/merger deal.

The Company is currently working
with Spectrum Medical Market Consultants to act as its representative in
Canada for its endoscopic instruments including the MammoView® devices.
Solos Endoscopy experienced significant back orders during the first six months
of 2014 due to supply issues related to a component manufacturer.

We are pleased to inform the shareholders that we have resolved the (component manufacturer) issues and have resumed
shipping to hospitals this past week. We expect sales and cash flow to improve
over the next 90 days. In the last six months, fifteen new hospitals have begun to
carry Solos Endoscopy instruments. This includes a select number of hospitals
who are now carrying the MammoView® product line.

http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610